SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-027960
Filing Date
2024-03-29
Accepted
2024-03-29 16:01:14
Documents
15
Period of Report
2024-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0202918-8k_inmune.htm   iXBRL 8-K 28433
2 PRESS RELEASE FOR FINANCIAL RESULTS AND BUSINESS UPDATE ea020291801ex99-1_inmune.htm EX-99.1 87831
3 GRAPHIC ex99-1_001.jpg GRAPHIC 1894
  Complete submission text file 0001213900-24-027960.txt   307373

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20240328.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20240328_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20240328_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0202918-8k_inmune_htm.xml XML 3720
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

IRS No.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 24804081
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)